Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma

• Published in: World journal of gastroenterology : WJG Vol. 14; no. 13; pp. 1997 - 2002
• Main Authors: Taniguchi, Miyuki, Kim, Soo-Ryang, Imoto, Susumu, Ikawa, Hirotsugu, Ando, Kenji, Mita, Keiji, Fuki, Shuichi, Sasase, Noriko, Matsuoka, Toshiyuki, Kudo, Masatoshi, Hayashi, Yoshitake
• Format: Journal Article
• Language: English
• Published: United States Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan%Department of Radiology, Osaka City University Medical School, Osaka, Japan%Department of Gastroenterology, Kinki University School of Medicine, Osakasayama,Japan%Division of Molecular Medicine &Medical Genetics, International Center for Medical Research and Treatment (ICMRT), Kobe University Graduate School of Medicine, Kobe, Japan 07-04-2008; The WJG Press and Baishideng
• Subjects: Adolescent; Adult; Carcinoma, Hepatocellular - therapy; Chemoembolization, Therapeutic - methods; Ethanol - administration & dosage; Female; Humans; Liver Cancer; Liver Neoplasms - therapy; Male; Middle Aged; Prognosis; Recurrence; Time Factors; Treatment Outcome; Ultrasonography; 治疗方法; 经皮乙醇注射; 肝切除术; 肝细胞癌; Hepatocellular carcinoma; Interventional ablation; Prognosis; Percutaneous ethanol injection; Ultrasound
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.14.1997

AIM： To evaluate long-term follow-up of minimum-sized hepatocellular carcinoma （HCC） treated with percutaneous ethanol injection （PEI）. METHODS： PEI was applied to 42 lesions in 31 patients （23 male and eight female） with HCC 〈 15 mm in diameter, over the past 15 years. RESULTS： Overall survival rate was 74.1% at 3 years, 49.9% at 5 years, 27.2% at 7 years and 14.5% at 10 years. These results are superior to, or at least the same as those for hepatic resection and radiofrequency ablation. Survival was affected only by liver function, but not by sex, age, etiology of Hepatitis B virus or Hepatitis C virus, α-fetoprotein levels, arterial and portal blood flow, histological characteristics, and tumor multiplicity or size. Patients in Chiid-Pugh class A and B had 5-, 7- and 10-years survival rates of 76.0%, 42.2% and 15.8%, and 17.1%, 8.6% and 0%, respectively （P = 0.025）. CONCLUSION： Treatment with PEI is best indicated for patients with HCC 〈 15 mm in Child-Pugh class A.